These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 9382447)
21. [Chemotherapy-induced cardiac toxicity and management]. Komagata H; Sakai H Gan To Kagaku Ryoho; 2003 Jun; 30(6):787-92. PubMed ID: 12852345 [TBL] [Abstract][Full Text] [Related]
22. Drug may protect children's hearts from chemotherapy. McBride D ONS Connect; 2010 Dec; 25(12):15. PubMed ID: 21214085 [No Abstract] [Full Text] [Related]
23. Extravasation: a dreaded complication of chemotherapy. Schrijvers DL Ann Oncol; 2003; 14 Suppl 3():iii26-30. PubMed ID: 12821535 [No Abstract] [Full Text] [Related]
24. [Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice]. Gershanovich ML Vopr Onkol; 2001; 47(1):119-22. PubMed ID: 11317530 [No Abstract] [Full Text] [Related]
25. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. van Dalen EC; Michiels EM; Caron HN; Kremer LC Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231 [TBL] [Abstract][Full Text] [Related]
27. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Anderson B Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251 [TBL] [Abstract][Full Text] [Related]
28. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer. Bárdi E; Bobok I; V Oláh A; Kappelmayer J; Kiss C Pathol Oncol Res; 2007; 13(3):249-53. PubMed ID: 17922055 [TBL] [Abstract][Full Text] [Related]
36. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia? Silber JH Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791 [No Abstract] [Full Text] [Related]
37. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836 [TBL] [Abstract][Full Text] [Related]
38. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. Swain SM; Vici P J Cancer Res Clin Oncol; 2004 Jan; 130(1):1-7. PubMed ID: 14564513 [TBL] [Abstract][Full Text] [Related]
39. [The use of Cardioxane in chemotherapy of malignant neoplasms in children]. Safonova SA; Punanov IuA; Dedukh VM; Kolygin BA Vopr Onkol; 1997; 43(4):459-61. PubMed ID: 9381706 [TBL] [Abstract][Full Text] [Related]
40. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Schiavetti A; Castello MA; Versacci P; Varrasso G; Padula A; Ventriglia F; Werner B; Colloridi V Pediatr Hematol Oncol; 1997; 14(3):213-22. PubMed ID: 9185206 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]